On April 25, 2024, NeuroSense Therapeutics Ltd., closed the transaction. The transaction included participation from single investor. As a part of the transaction, the company paid CAD 50,000 cash fee and 70,964 of the ordinary shares of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | +14.81% |
|
+46.57% | +57.96% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.96% | 2.24Cr | |
+16.44% | 12TCr | |
+18.94% | 11TCr | |
+18.89% | 2.62TCr | |
-25.37% | 1.9TCr | |
-19.77% | 1.57TCr | |
-20.20% | 1.52TCr | |
-47.37% | 1.47TCr | |
+59.91% | 1.46TCr | |
+4.35% | 1.38TCr |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- NeuroSense Therapeutics Ltd. announced that it has received $4.47 million in funding